Ekiz, Hüseyin Atakan
Loading...
Profile URL
Name Variants
Ekiz, Huseyin Atakan
Ekiz, Hüseyin A.
Ekiz, Huseyin A.
Ekiz, H. Atakan
Ekiz, H.A.
Ekiz, H. A.
Ekiz, H.
Ekiz, Atakan
Ekiz, Hüseyin A.
Ekiz, Huseyin A.
Ekiz, H. Atakan
Ekiz, H.A.
Ekiz, H. A.
Ekiz, H.
Ekiz, Atakan
Job Title
Email Address
atakanekiz@iyte.edu.tr
Main Affiliation
04.03. Department of Molecular Biology and Genetics
Status
Current Staff
Website
ORCID ID
Scopus Author ID
Turkish CoHE Profile ID
Google Scholar ID
WoS Researcher ID
Sustainable Development Goals
1NO POVERTY
0
Research Products
2ZERO HUNGER
0
Research Products
3GOOD HEALTH AND WELL-BEING
21
Research Products
4QUALITY EDUCATION
0
Research Products
5GENDER EQUALITY
0
Research Products
6CLEAN WATER AND SANITATION
0
Research Products
7AFFORDABLE AND CLEAN ENERGY
0
Research Products
8DECENT WORK AND ECONOMIC GROWTH
0
Research Products
9INDUSTRY, INNOVATION AND INFRASTRUCTURE
4
Research Products
10REDUCED INEQUALITIES
0
Research Products
11SUSTAINABLE CITIES AND COMMUNITIES
0
Research Products
12RESPONSIBLE CONSUMPTION AND PRODUCTION
0
Research Products
13CLIMATE ACTION
0
Research Products
14LIFE BELOW WATER
0
Research Products
15LIFE ON LAND
0
Research Products
16PEACE, JUSTICE AND STRONG INSTITUTIONS
0
Research Products
17PARTNERSHIPS FOR THE GOALS
0
Research Products
Documents
37
Citations
808
h-index
18
Documents
56
Citations
1156
Scholarly Output
35
Articles
18
Views / Downloads
71051/7552
Supervised MSc Theses
6
Supervised PhD Theses
0
WoS Citation Count
277
Scopus Citation Count
296
Patents
0
Projects
1
WoS Citations per Publication
7.91
Scopus Citations per Publication
8.46
Open Access Source
19
Supervised Theses
6
| Journal | Count |
|---|---|
| Hematology | 3 |
| FEBS Open Bio | 2 |
| Journal of Immunology | 2 |
| Haematologica | 2 |
| Cancers | 1 |
Current Page: 1 / 5
Scopus Quartile Distribution
Competency Cloud
35 results
Scholarly Output Search Results
Now showing 1 - 10 of 35
Master Thesis Development of Visual Analysis Interfaces for Large Biological Data and Characterization of Immunomodulatory Noncoding Rna Networks Cancer(01. Izmir Institute of Technology, 2023) Kuş, Muhammet Emre; Ekiz, Hüseyin Atakan; Ekiz, Hüseyin AtakanThese days we are collecting data in higher and higher dimensions, processing it, and developing tools that have strong descriptive and predictive powers. Especially in the field of cancer, the processing of data collected from patients has substantial potential in terms of discovering new biomarkers, developing personalized treatment methods, and better prognosticators. However, there are significant difficulties in utilizing and analyzing high-dimensional data. A good level of coding skills is required to bring the data together and apply different analysis methods. With the visual interfaces created in this study, we offer the opportunity to examine and analyze the high-dimensional data of thousands of cancer patients, which are open to the public through The Cancer Genome Atlas initiative, especially for bench scientists who has no prior coding expertise. The Cancer Genome Explorer, shortly TCGEx, is a robust bioinformatic tool that we developed to facilitate high-throughput cancer data analysis through several sophisticated algorithms. With special features like subset-specific analysis and comparative analysis by using multiple cancer data, TCGEx can contribute to the literature by accelerating the studies, especially in hypothesis-driven research. This study also describes a use-case scenario that demonstrates how hypothesis-driven research can be performed using TCGExplorer for melanoma. In melanoma, elucidating the interactions between the tumor and the immune system at the miRNA level is crucial for developing new therapeutics. In this study, we characterize the properties of potential therapeutic targets that act on tumor and immune cells, which we have identified using various statistical analysis methods including machine learning, dimensionality reduction, and survival modeling using the TCGEx portal.Conference Object Suppression of STAT5A Increases Chemotherapeutic Sensitivity in Imatinib-Resistant and Imatinib-Sensitive K562 Cells(Ferrata Storti Foundation, 2010) Baran, Y.; Baran, Yusuf; Kosova, B.; Ekiz, Hüseyin Atakan; Tezcanli, B.; Ekiz, H.; Cakir, Z.; Selvi, S.Article Citation - WoS: 22Citation - Scopus: 23A Single-Amino Acid Substitution in the Adaptor Lat Accelerates Tcr Proofreading Kinetics and Alters T-Cell Selection, Maintenance and Function(Nature Portfolio, 2023) Lo, Wan-Lin; Ekiz, Hüseyin Atakan; Kuhlmann, Miriam; Rizzuto, Gabrielle; Ekiz, H. Atakan; Kolawole, Elizabeth M.; Revelo, Monica P.; Andargachew, RakiebMature T cells must discriminate between brief interactions with self-peptides and prolonged binding to agonists. The kinetic proofreading model posits that certain T-cell antigen receptor signaling nodes serve as molecular timers to facilitate such discrimination. However, the physiological significance of this regulatory mechanism and the pathological consequences of disrupting it are unknown. Here we report that accelerating the normally slow phosphorylation of the linker for activation of T cells (LAT) residue Y136 by introducing an adjacent Gly135Asp alteration (LAT(G135D)) disrupts ligand discrimination in vivo. The enhanced self-reactivity of LAT(G135D) T cells triggers excessive thymic negative selection and promotes T-cell anergy. During Listeria infection, LAT(G135D) T cells expand more than wild-type counterparts in response to very weak stimuli but display an imbalance between effector and memory responses. Moreover, despite their enhanced engagement of central and peripheral tolerance mechanisms, mice bearing LAT(G135D) show features associated with autoimmunity and immunopathology. Our data reveal the importance of kinetic proofreading in balancing tolerance and immunity. Lo and colleagues provide evidence for the TCR kinetic proofreading model by LAT Gly135Asp alteration to reveal functional consequences of altered kinetics in TCR activation in thymic selection and mature T-cell responses.Master Thesis Neuroblastoma Ras (NRAS) Mutasyonlu Melanomda Negative Regulator Of Antiviral Response (NRAV) Uzun Kodlamayan RNA'nın Tip-2 İnterferon Yanıtındaki Rollerinin İncelenmesi ve Uzun Kodlamayan RNA İfade Örüntülerinin İmmünoterapi Yanıtıyla İlişkilerinin Araştırılması(2025) Şahin, Çağatay; Ekiz, Hüseyin Atakan; Güner, Şerife AyazBu çalışma, uzun kodlamayan RNA (lncRNA) NRAV'ın tip II interferon (IFN-γ) sinyal yolaklarını düzenlemedeki rolünü ve bunun melanoma biyolojisi ile immünoterapi etkinliği üzerindeki etkilerini incelemektedir. NRAS mutasyonuna sahip SKMEL147 melanoma hücre hattı kullanılarak, IFN-γ uyarımı öncesi ve sonrası koşullarda interferonla uyarılan genlerin (ISG) ekspresyonu, hücre proliferasyonu ve hücre ölümü üzerindeki değişiklikleri değerlendirmek amacıyla NRAV aşırı ifade eden hücre modelleri oluşturulmuştur. NRAV'ın aşırı ifadesi, IFIT2, IRF1 ve PD-L1 gibi kritik ISG'leri baskılayarak IFN-γ–STAT1 sinyal yolunun inhibe edildiğini göstermiştir. Fonksiyonel olarak, NRAV hücre büyümesini azaltmış ve hücre ölümünü nekroza kaydırmıştır; bu bulgu koloni oluşum deneyleri ve akış sitometrisi ile doğrulanmıştır. RNA pulldown sonrası yapılan proteomik analiz, NRAV ile ilişkili proteinlerin otofaji, translasyon ve mitokondriyal stres yanıtlarında rol aldığını ortaya koyarak, NRAV'ın hücre kaderini post-transkripsiyonel düzeyde düzenleyebileceğini göstermiştir. Melanoma immünoterapisi veri setlerine uygulanan makine öğrenmesi, LINC02273, LINC01833 ve MIR210HG gibi immünoterapiye yanıtla ilişkili olabilecek çok sayıda lncRNA'yı belirlemiş, ZFAT-AS1 ve CSRP3-AS1 gibi yeni adayları da ortaya koymuştur. Bu bulgular, NRAV'ın hem IFN aracılı bağışıklığı baskılayıcı hem de nekrotik hücre ölümünü düzenleyici ikili işlevine dikkat çekmekte olup, onu gelecekteki mekanistik ve terapötik çalışmalar için potansiyel bir hedef haline getirmektedir. Bu araştırma, melanomada bağışıklık düzenleyici lncRNA'ların anlaşılmasını derinleştirerek, immünoterapi direncinde biyobelirteç ve hedef keşfi için yeni yollar açmaktadır.Master Thesis MikroRNA-150'nin Melanoma Progresyonu ve İmmün Mikroçevre Düzenlemesindeki Rolünün Araştırılması(2025) Ağır, Zekiye Büşra; Ekiz, Hüseyin AtakanMelanom, yüksek mutasyon yükü ve metastatik kapasitesi nedeniyle agresif bir kanser türüdür. Bu agresifliğe katkı sağlayan birçok yolak bulunmakta olup, mikroRNA'ların bu süreçte önemli bir rol oynadığı bilinmektedir. miR-150, hem tümör hücrelerinde hem de bağışıklık sisteminde işlev görebilen çok işlevli bir mikroRNA'dır; ancak melanomdaki rolü yeterince araştırılmamıştır. Bu çalışmada, miR-150'nin melanom progresyonu ve tümör bağışıklık mikroçevresi üzerindeki etkileri hem in vitro hem de in vivo deneysel modeller ve biyoinformatik yaklaşımlar kullanılarak incelenmiştir. B16F10-OVA melanom hücrelerinde CRISPR/Cas9 yöntemiyle miR-150 genetik olarak silinmiş ve proliferasyon, koloni oluşturma ve migrasyon üzerindeki etkileri in vitro olarak değerlendirilmiştir. Bu analizlerde hücre kültürü sistemlerinde anlamlı bir farklılık gözlenmemiştir. İn vivo çalışmalar ise miR-150 silinmesinin tümör bağışıklık mikroçevresinde bazı değişikliklere yol açmasına rağmen tutarlı bir etki göstermemiştir. Tümör hücresine özgü etkilerin ötesinde, melanom transkriptomik verileri analiz edilerek miR-150 ekspresyonunun tümör mikroçevresindeki ilişkileri değerlendirilmiştir. miR-150 ekspresyonunun sağkalım, inflamasyon ve bağışıklık yanıtları ile ilişkili olduğu bulunmuştur. Bu bulgular, miR-150'nin yalnızca tümör hücrelerinde değil, aynı zamanda tümör mikroçevresindeki bağışıklık hücrelerinde de işlevsel roller üstlenebileceğini düşündürmektedir.Article Citation - WoS: 6Citation - Scopus: 6Bioactive Sphingolipids in Response To Chemotherapy: a Scope on Leukemias(Bentham Science Publishers B.V., 2011) Ekiz, Hüseyin Atakan; Baran, YusufSphingolipids are major constituents of the cells with emerging roles in the regulation of cellular processes. Deregulation of sphingolipid metabolism is reflected as various pathophysiological conditions including metabolic disorders and several forms of cancer. Ceramides, ceramide-1-phosphate (C1P), glucosyl ceramide (GluCer), sphingosine and sphingosine-1-phosphate (S1P) are among the bioactive sphingolipid species that have important roles in the regulation of cell death, survival and chemotherapeutic resistance. Some of those species are known to accumulate in the cells upon chemotherapy while some others are known to exhibit an opposite pattern. Even though the length of fatty acid chain has a deterministic effect, in general, upregulation of ceramides and sphingosine is known to induce apoptosis. However, S1P, C1P and GluCer are proliferative for cells and they are involved in the development of chemoresistance. Therefore, sphingolipid metabolism appears as a good target for the development of novel therapeutics or supportive interventions to increase the effectiveness of the chemotherapeutic drugs currently in hand. Some approaches involve manipulation of the synthesis pathways yielding the increased production of apoptotic sphingolipids while the proliferative ones are suppressed. Some others are trying to take advantage of cytotoxic sphingolipids like short chain ceramide analogs by directly delivering them to the malignant cells as a distinct chemotherapeutic intervention. Numerous studies in the literature show the feasibility of those approaches especially in acute and chronic leukemias. This review compiles the current knowledge about sphingolipids and their roles in chemotherapeutic response with the particular attention to leukemias. © 2011 Bentham Science Publishers Ltd.Conference Object Exploring Breast Cancer Immune Microenvironment Through an Interactive Analysis Platform(Wiley, 2025) Ekiz, H. A.Conference Object Therapeutic Potential of Targeting Sphingolipid Signaling Pathways in Various Types of Cancers(Pergamon-elsevier Science Ltd, 2010) Baran, Y.; Bassoy, E. Y.; Cakir, Z.; Camgoz, A.; Gencer, E. B.; Kartal, M.; Gucluler, G.Article Citation - WoS: 9Citation - Scopus: 11Mir-Aculous New Avenues for Cancer Immunotherapy(Frontiers Media S.A., 2022) Tang, William W.; Bauer, Kaylyn M.; Barba, Cindy; Ekiz, Hüseyin Atakan; O’Connell, Ryan M.The rising toll of cancer globally necessitates ingenuity in early detection and therapy. In the last decade, the utilization of immune signatures and immune-based therapies has made significant progress in the clinic; however, clinical standards leave many current and future patients without options. Non-coding RNAs, specifically microRNAs, have been explored in pre-clinical contexts with tremendous success. MicroRNAs play indispensable roles in programming the interactions between immune and cancer cells, many of which are current or potential immunotherapy targets. MicroRNAs mechanistically control a network of target genes that can alter immune and cancer cell biology. These insights provide us with opportunities and tools that may complement and improve immunotherapies. In this review, we discuss immune and cancer cell–derived miRNAs that regulate cancer immunity and examine miRNAs as an integral part of cancer diagnosis, classification, and therapy.Review Citation - WoS: 5Citation - Scopus: 5Breast Cancer Immunity: It Is Time for the Next Chapter(Cold Spring Harbor Lab Press, Publications dept, 2024) Quail, Daniela F.; Park, Morag; Welm, Alana L.; Ekiz, H. AtakanOur ability to interrogate the tumor immune microenvironment (TIME) at an ever-increasing granularity has uncovered critical determinants of disease progression. Not only do we now have a better understanding of the immune response in breast cancer, but it is becoming possible to leverage key mechanisms to effectively combat this disease. Almost every component of the immune system plays a role in enabling or inhibiting breast tumor growth. Building on early seminal work showing the involvement of T cells and macrophages in controlling breast cancer progression and metastasis, single-cell genomics and spatial proteomics approaches have recently expanded our view of the TIME. In this article, we provide a detailed description of the immune response against breast cancer and examine its heterogeneity in disease subtypes. We discuss preclinical models that enable dissecting the mechanisms responsible for tumor clearance or immune evasion and draw parallels and distinctions between human disease and murine counterparts. Last, as the cancer immunology field is moving toward the analysis of the TIME at the cellular and spatial levels, we highlight key studies that revealed previously unappreciated complexity in breast cancer using these technologies. Taken together, this article summarizes what is known in breast cancer immunology through the lens of translational research and identifies future directions to improve clinical outcomes.